Galidesivir

From WikiMD.org
Jump to navigation Jump to search

Galidesivir

Galidesivir (pronounced gah-lee-deh-see-veer) is an antiviral drug currently under investigation for its potential use in the treatment of various viral diseases. The drug was initially developed by BioCryst Pharmaceuticals, a company specializing in the development of small molecule drugs that block key enzymes involved in the pathogenesis of diseases.

Etymology

The name "Galidesivir" is a portmanteau of the words "Gali" and "desivir". The exact etymology is not known, but "desivir" is a common suffix in the names of antiviral drugs.

Mechanism of Action

Galidesivir is a broad-spectrum antiviral that works by inhibiting the RNA polymerase enzyme, which is essential for viral replication. By blocking this enzyme, Galidesivir prevents the virus from replicating within the host's cells.

Clinical Trials

Galidesivir has been tested in clinical trials for its efficacy against several viruses, including the Zika virus, Ebola virus, and the Marburg virus. It is also being investigated for potential use against the SARS-CoV-2 virus, which causes COVID-19.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski